Page 4 - Eli Lilly

Eli Lilly expects to launch obesity drug in India next year, says CEO

Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both conditions

Eli Lilly closer to joining Magnificent Seven in $1 trn market cap club

"Could Lilly be the first $1 trillion biopharma stock?" Morgan Stanley's Terence Flynn and colleagues asked in a note to clients. "We continue to see a path for further upside"

USFDA finds new manufacturing lapses at pharma co Eli Lilly's plant: Report

Lilly said in a statement to Reuters that the inspection followed a company request to the FDA to make a change to its manufacture of migraine treatment Emgality

Eli Lilly's 'triple G' anti-obesity drug leads to 24% weight loss in trial

The pharma company published the results of phase two of the clinical trial of Retatrutide, showing impressive weight loss and regulation of blood sugar levels in undertrials

Suven starts Phase 3 trial for first home-grown Alzheimer's drug

Clinical trial randomisation is the process of assigning patients by chance to groups that receive different treatments

What is Twitter's blue tick?

Twitter's move to sell its blue check badge for $8 made aerospace company Lockheed Martin and pharma giant Eli Lilly & Co fall prey to impersonators. What is blue check? How did it come into being?

Twitter's big headache: Brand impostors thanks to the $8 verification

Users started creating accounts pretending to be major brands and politicians, fooling users and potentially jeopardizing Twitter's now-shaky reputation with top advertisers

Experimental obesity drug may be alternative to bariatric surgery

The drug maker claimed that the new drug Tirzepatide has enabled people with obesity or who are overweight to lose about 22.5 per cent of their body weight

Cipla to sell Eli Lilly's insulin products Humalog, Trulicity in India

Only 3 firms - Novo Nordisk, Sanofi, and Eli Lilly - supply insulin to patients in the US. These three companies, commonly called the 'Big Three', control over 90 per cent of the global insulin market

Bajaj Healthcare seeks compulsory licence for Covid-19 drug Baricitinib

Eli Lilly has granted voluntary license to 6 Indian drugmakers for Baricitinib

Eli Lilly to seek FDA approval for potential Alzheimer's drug

Shares of Eli Lilly and Co. jumped more than 8%, or $18.59, to $235.69 at the opening bell Thursday.

Eli Lilly memo says firm did not make false statements to FDA

(Reuters) - A week before Eli Lilly disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing there, according to a company memo reviewed by Reuters.

BDR Pharma inks licensing pact with Eli Lilly for Covid-19 treatment drug

Drug firm BDR Pharma on Wednesday said it has inked a licensing pact with Eli Lilly and Company for the manufacturing and distribution of Baricitinib for the treatment of Covid-19 in India

Eli Lilly inks pact with Natco Pharma for Covid-19 drug baricitinib

Drug firm Eli Lilly said it has signed a voluntary licensing agreement with Natco Pharma to further expedite the availability of baricitinib for Covid-19 patients in India

Torrent Pharma inks pact with Eli Lilly for Covid drug Baricitinib in India

Under royalty-free, non-exclusive deal, Torrent can make and sell baricitinib in India along with the US firm's other license partners

Lilly signs 3 pacts to expand availability of baricitinib for Covid patient

Eli Lilly has issued additional royalty-free, non-exclusive voluntary licenses to Dr Reddy's Ltd, MSN Laboratories and Torrent Pharmaceuticals

Eli Lilly signs licensing pact with Cipla, Sun, Lupin for Covid-19 drug

Olumiant, or Baricitinib, is an oral drug developed by US biopharmaceutical major, Incyte Corporation, and licensed to Eli Lilly

Eli Lilly signs deals to boost supply of Covid-19 treatment in India

The firm has signed licensing agreements with three Indian generic drugmakers to expand the availability of the drug baricitinib

Cipla inks pact with Eli Lilly to produce, sell Covid-19 treatment drug

Drug major Cipla on Monday said it has inked a pact with US-based Eli Lilly and Company to manufacture and produce baricitinib in the country for the treatment of Covid-19

Insider alleges Eli Lilly blocked her efforts to sound alarms on drug plant

Lilly is working closely with the FDA to address concerns about the factory,